The Asia-Pacific fertility services market was valued at $4,529.06 million in 2020, and is expected to reach $20,492.95 million by 2030, registering a CAGR of 15.5% from 2021 to 2030.
Fertility services support the treatments used to cure infertility. These services often include techniques like artificial insemination, in vitro fertilization (IVF), surrogacy, and others, which aid single parents, the lesbian, gay, bisexual, and transgender (LGBT) community, and couples with infertility problems to reproduce.
The Asia-Pacific fertility services market is projected to witness huge growth during the forecast period, owing to the emerging trend of delayed pregnancies among women, rise in technological advancements in fertility procedures, high incidence of infertility cases, and increased rate of sperms and ovum donations. Furthermore, a rise in awareness regarding fertility issues, increase in disposable income, availability of fertility treatments, and favorable reimbursement policies further augment the market growth. China dominated the Asia-Pacific fertility services market in 2020 and is expected to register the highest CAGR during the forecast period. This is attributed to increase in awareness and acceptance within the country for adopting fertility services.
In addition, the recent innovations in different fertility services, such as preimplantation genetic screening have helped patients have a child unaffected by any genetic disease. Capsule IVF and embryoscopes have also been novel treatment procedures being used extensively in hospitals and IVF clinics. Furthermore, intracytoplasmic sperm injections have allowed the would-be infertile men in becoming fathers. This way, technology has been one of the most favorable drivers for the growth of the market, however, stringent regulations regarding the use of certain fertility procedures such as surrogacy and ethical considerations associated with these procedures have hindered market growth. On the other hand, the rise in medical tourism in the Asia-Pacific region has augmented the growth of the fertility services market.
The Asia-Pacific fertility services market is classified into procedure, service, end user, and country. By procedure, the market is divided into IVF with intracytoplasmic sperm injection (ICSI), surrogacy, IVF without ICSI (intracytoplasmic sperm injection), intrauterine insemination (IUI), surrogacy, and others. By service, it is categorized into fresh non-donor, frozen non-donor, egg & embryo banking, fresh donor, and frozen donor. By end user, the market is segmented into fertility clinics, hospitals, surgical centers, and clinical research institutes. By country, the market is analyzed across Japan, India, China, Australia, South Korea, Thailand, Malaysia, Singapore, New Zealand, Philippines, Indonesia, and the Rest of Asia-Pacific.
The Asia-Pacific fertility services market is projected to witness huge growth during the forecast period, owing to the emerging trend of delayed pregnancies among women, rise in technological advancements in fertility procedures, high incidence of infertility cases, and increased rate of sperms and ovum donations. Furthermore, a rise in awareness regarding fertility issues, increase in disposable income, availability of fertility treatments, and favorable reimbursement policies further augment the market growth. China dominated the Asia-Pacific fertility services market in 2020 and is expected to register the highest CAGR during the forecast period. This is attributed to increase in awareness and acceptance within the country for adopting fertility services.
In addition, the recent innovations in different fertility services, such as preimplantation genetic screening have helped patients have a child unaffected by any genetic disease. Capsule IVF and embryoscopes have also been novel treatment procedures being used extensively in hospitals and IVF clinics. Furthermore, intracytoplasmic sperm injections have allowed the would-be infertile men in becoming fathers. This way, technology has been one of the most favorable drivers for the growth of the market, however, stringent regulations regarding the use of certain fertility procedures such as surrogacy and ethical considerations associated with these procedures have hindered market growth. On the other hand, the rise in medical tourism in the Asia-Pacific region has augmented the growth of the fertility services market.
The Asia-Pacific fertility services market is classified into procedure, service, end user, and country. By procedure, the market is divided into IVF with intracytoplasmic sperm injection (ICSI), surrogacy, IVF without ICSI (intracytoplasmic sperm injection), intrauterine insemination (IUI), surrogacy, and others. By service, it is categorized into fresh non-donor, frozen non-donor, egg & embryo banking, fresh donor, and frozen donor. By end user, the market is segmented into fertility clinics, hospitals, surgical centers, and clinical research institutes. By country, the market is analyzed across Japan, India, China, Australia, South Korea, Thailand, Malaysia, Singapore, New Zealand, Philippines, Indonesia, and the Rest of Asia-Pacific.
KEY BENEFITS FOR STAKEHOLDERS
- The study provides an in-depth analysis of the Asia-Pacific fertility services market, and the current trends and future estimations to elucidate the imminent investment pockets
- It presents a quantitative analysis of the market from 2021 to 2030 to enable stakeholders to capitalize on the prevailing market opportunities
- Extensive analysis of the market based on procedures, services, and end users assists to understand the trends in the industry
- Key players and their strategies are thoroughly analyzed to understand the competitive outlook of the market
KEY MARKET SEGMENTS
By Procedure
- IVF with ICSI
- IUI
- IVF without ICSI
- Surrogacy
- Others
By Service
- Fresh Non-donor
- Frozen Non-donor
- Egg & Embryo Banking
- Fresh Donor
- Frozen Donor
By End User
- Fertility Clinics
- Hospitals
- Surgical Centers
- Clinical Research Institutes
By Country
- Japan
- India
- China
- Australia
- South Korea
- Thailand
- Malaysia
- Singapore
- New Zealand
- Philippines
- Indonesia
- Rest of Asia-Pacific
LIST OF KEY PLAYERS PROFILED IN THE REPORT
- Apollo Hospitals Enterprise Ltd
- CooperSurgical, Inc.
- City Fertility
- ESCO Life Sciences Group
- Fertility Associates Limited
- Genea Limited
- Medicover Group
- Monash IVF Group Limited
- Thermo Fisher Scientific Inc.
- Virtus Health
Table of Contents
CHAPTER 1: INTRODUCTION1.1. Report description1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2: EXECUTIVE SUMMARY2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. Porter’s five force analysis
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Continuous decline in fertility rates
3.4.1.2. Delayed pregnancies in women
3.4.1.3. Technological advancements with respect to fertility treatment
3.4.2. Restraints
3.4.2.1. High treatment costs of ARTs in emerging countries
3.4.2.2. Inadequate reimbursement policies
3.4.3. Opportunity
3.4.3.1. Rise in fertility tourism
3.5. COVID-19 impact on the fertility services market
CHAPTER 4: FERTILITY SERVICES MARKET, BY PROCEDURE4.1. Overview
4.1.1. Market size and forecast
4.2. IVF with ICSI
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast
4.3. IUI
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast
4.4. IVF without ICSI
4.4.1. Key market trends growth factors, and opportunities
4.4.2. Market size and forecast
4.5. Surrogacy
4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast
4.6. Others
4.6.1. Key market trends, growth factors, and opportunities
4.6.2. Market size and forecast
CHAPTER 5: FERTILITY SERVICES MARKET, BY SERVICE5.1. Overview
5.1.1. Market size and forecast
5.2. Fresh non-donor
5.2.1. Key market trends, growth factors, and opportunities
5.2.2. Market size and forecast
5.3. Frozen non-donor
5.3.1. Key market trends, growth factors, and opportunities
5.3.2. Market size and forecast
5.4. Egg & embryo banking
5.4.1. Key market trends, growth factors, and opportunities
5.4.2. Market size and forecast
5.5. Fresh donor
5.5.1. Key market trends, growth factors, and opportunities
5.5.2. Market size and forecast
5.6. Frozen donor
5.6.1. Key market trends, growth factors, and opportunities
5.6.2. Market size and forecast
CHAPTER 6: FERTILITY SERVICES MARKET, BY END USER6.1. Overview
6.1.1. Market size and forecast
6.2. Fertility clinics
6.2.1. Key market trends, growth factors, and opportunities
6.2.2. Market size and forecast
6.3. Hospitals
6.3.1. Key market trends, growth factors, and opportunities
6.3.2. Market size and forecast
6.4. Surgical centers
6.4.1. Key market trends, growth factors, and opportunities
6.4.2. Market size and forecast
6.5. Clinical research institutes
6.5.1. Key market trends, growth factors, and opportunities
6.5.2. Market size and forecast
CHAPTER 7: ASIA-PACIFIC FERTILITY SERVICES MARKET, BY COUNTRY7.1. Overview
7.1.1. Market size and forecast
7.2. Japan
7.2.1. Market size and forecast, by procedure
7.2.2. Market size and forecast, by service
7.2.3. Market size and forecast, by end user
7.3. India
7.3.1. Market size and forecast, by procedure
7.3.2. Market size and forecast, by service
7.3.3. Market size and forecast, by end user
7.4. China
7.4.1. Market size and forecast, by procedure
7.4.2. Market size and forecast, by service
7.4.3. Market size and forecast, by end user
7.5. Australia
7.5.1. Market size and forecast, by procedure
7.5.2. Market size and forecast, by service
7.5.3. Market size and forecast, by end user
7.6. South Korea
7.6.1. Market size and forecast, by procedure
7.6.2. Market size and forecast, by service
7.6.3. Market size and forecast, by end user
7.7. Thailand
7.7.1. Market size and forecast, by procedure
7.7.2. Market size and forecast, by service
7.7.3. Market size and forecast, by end user
7.8. Malaysia
7.8.1. Market size and forecast, by procedure
7.8.2. Market size and forecast, by service
7.8.3. Market size and forecast, by end user
7.9. Singapore
7.9.1. Market size and forecast, by procedure
7.9.2. Market size and forecast, by service
7.9.3. Market size and forecast, by end user
7.10. New Zealand
7.10.1. Market size and forecast, by procedure
7.10.2. Market size and forecast, by service
7.10.3. Market size and forecast, by end user
7.11. Philippines
7.11.1. Market size and forecast, by procedure
7.11.2. Market size and forecast, by service
7.11.3. Market size and forecast, by end user
7.12. Indonesia
7.12.1. Market size and forecast, by procedure
7.12.2. Market size and forecast, by service
7.12.3. Market size and forecast, by end user
7.13. Rest of Asia-Pacific
7.13.1. Market size and forecast, by procedure
7.13.2. Market size and forecast, by service
7.13.3. Market size and forecast, by end user
CHAPTER 8: COMPANY PROFILES8.1. APOLLO HOSPITALS ENTERPRISE LTD.
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.1.6. Key strategic moves and developments
8.2. CITY FERTILITY
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Key strategic moves and developments
8.3. COOPERSURGICAL, INC.
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.3.6. Key strategic moves and developments
8.4. ESCO LIFE SCIENCES GROUP
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Key strategic moves and developments
8.5. FERTILITY ASSOCIATES LIMITED
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.6. GENEA LIMITED
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Key strategic moves and developments
8.7. MEDICOVER GROUP (MEDICOVER FERTILITY and FIRST EGG BANK)
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.8. MONASH IVF GROUP LIMITED
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.8.6. Key strategic moves and developments
8.9. THERMO FISHER SCIENTIFIC INC.
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business Performance
8.9.6. Key strategic moves and developments
8.10. VIRTUS HEALTH
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance
8.10.6. Key strategic moves and developments
List of Tables
TABLE 01. ASIA-PACIFIC FERTILITY SERVICES MARKET, BY PROCEDURE, 2020-2030 ($MILLION)
TABLE 02. ASIA-PACIFIC FERTILITY SERVICES MARKET, BY SERVICE, 2020-2030 ($MILLION)
TABLE 03. ASIA-PACIFIC FERTILITY SERVICES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 04. ASIA-PACIFIC FERTILITY SERVICES MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 05. JAPAN FERTILITY SERVICES MARKET, BY PROCEDURE, 2020-2030 ($MILLION)
TABLE 06. JAPAN FERTILITY SERVICES MARKET, BY SERVICE, 2020-2030 ($MILLION)
TABLE 07. JAPAN FERTILITY SERVICES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 08. INDIA FERTILITY SERVICES MARKET, BY PROCEDURE, 2020-2030 ($MILLION)
TABLE 09. INDIA FERTILITY SERVICES MARKET, BY SERVICE, 2020-2030 ($MILLION)
TABLE 10. INDIA FERTILITY SERVICES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 11. CHINA FERTILITY SERVICES MARKET, BY PROCEDURE, 2020-2030 ($MILLION)
TABLE 12. CHINA FERTILITY SERVICES MARKET, BY SERVICE, 2020-2030 ($MILLION)
TABLE 13. CHINA FERTILITY SERVICES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 14. AUSTRALIA FERTILITY SERVICES MARKET, BY PROCEDURE, 2020-2030 ($MILLION)
TABLE 15. AUSTRALIA FERTILITY SERVICES MARKET, BY SERVICE, 2020-2030 ($MILLION)
TABLE 16. AUSTRALIA FERTILITY SERVICES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 17. SOUTH KOREA FERTILITY SERVICES MARKET, BY PROCEDURE, 2020-2030 ($MILLION)
TABLE 18. SOUTH KOREA FERTILITY SERVICES MARKET, BY SERVICE, 2020-2030 ($MILLION)
TABLE 19. SOUTH KOREA FERTILITY SERVICES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 20. THAILAND FERTILITY SERVICES MARKET, BY PROCEDURE, 2020-2030 ($MILLION)
TABLE 21. THAILAND FERTILITY SERVICES MARKET, BY SERVICE, 2020-2030 ($MILLION)
TABLE 22. THAILAND FERTILITY SERVICES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 23. MALAYSIA FERTILITY SERVICES MARKET, BY PROCEDURE, 2020-2030 ($MILLION)
TABLE 24. MALAYSIA FERTILITY SERVICES MARKET, BY SERVICE, 2020-2030 ($MILLION)
TABLE 25. MALAYSIA FERTILITY SERVICES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 26. SINGAPORE FERTILITY SERVICES MARKET, BY PROCEDURE, 2020-2030 ($MILLION)
TABLE 27. SINGAPORE FERTILITY SERVICES MARKET, BY SERVICE, 2020-2030 ($MILLION)
TABLE 28. SINGAPORE FERTILITY SERVICES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 29. NEW ZEALAND FERTILITY SERVICES MARKET, BY PROCEDURE, 2020-2030 ($MILLION)
TABLE 30. NEW ZEALAND FERTILITY SERVICES MARKET, BY SERVICE, 2020-2030 ($MILLION)
TABLE 31. NEW ZEALAND FERTILITY SERVICES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 32. PHILIPPINES FERTILITY SERVICES MARKET, BY PROCEDURE, 2020-2030 ($MILLION)
TABLE 33. PHILIPPINES FERTILITY SERVICES MARKET, BY SERVICE, 2020-2030 ($MILLION)
TABLE 34. PHILIPPINES FERTILITY SERVICES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 35. INDONESIA FERTILITY SERVICES MARKET, BY PROCEDURE, 2020-2030 ($MILLION)
TABLE 36. INDONESIA FERTILITY SERVICES MARKET, BY SERVICE, 2020-2030 ($MILLION)
TABLE 37. INDONESIA FERTILITY SERVICES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 38. REST OF ASIA-PACIFIC FERTILITY SERVICES MARKET, BY PROCEDURE, 2020-2030 ($MILLION)
TABLE 39. REST OF ASIA-PACIFIC FERTILITY SERVICES MARKET, BY SERVICE, 2020-2030 ($MILLION)
TABLE 40. REST OF ASIA-PACIFIC FERTILITY SERVICES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 41. APOLLO HOSPITALS: COMPANY SNAPSHOT
TABLE 42. APOLLO HOSPITALS: OPERATING SEGMENTS
TABLE 43. APOLLO HOSPITALS: PRODUCT PORTFOLIO
TABLE 44. CITY FERTILITY: COMPANY SNAPSHOT
TABLE 45. CITY FERTILITY: PRODUCT PORTFOLIO
TABLE 46. COOPERSURGICAL: COMPANY SNAPSHOT
TABLE 47. COOPERSURGICAL: OPERATING SEGMENTS
TABLE 48. COOPERSURGICAL: PRODUCT PORTFOLIO
TABLE 49. ESCO: COMPANY SNAPSHOT
TABLE 50. ESCO: OPERATING SEGMENTS
TABLE 51. ESCO: PRODUCT PORTFOLIO
TABLE 52. FERTILITY ASSOCIATES: COMPANY SNAPSHOT
TABLE 53. FERTILITY ASSOCIATES: OPERATING SEGMENTS
TABLE 54. FERTILITY ASSOCIATES: PRODUCT PORTFOLIO
TABLE 55. GENEA LIMITED: COMPANY SNAPSHOT
TABLE 56. GENEA LIMITED: OPERATING SEGMENTS
TABLE 57. GENEA LIMITED: PRODUCT PORTFOLIO
TABLE 58. MEDICOVER: COMPANY SNAPSHOT
TABLE 59. MEDICOVER: OPERATING SEGMENTS
TABLE 60. MEDICOVER: PRODUCT PORTFOLIO
TABLE 61. MVF: COMPANY SNAPSHOT
TABLE 62. MVF: PRODUCT PORTFOLIO
TABLE 63. THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT
TABLE 64. THERMO FISHER SCIENTIFIC: OPERATING SEGMENTS
TABLE 65. THERMO FISHER SCIENTIFIC: PRODUCT PORTFOLIO
TABLE 66. VIRTUS HEALTH: COMPANY SNAPSHOT
TABLE 67. VIRTUS HEALTH: OPERATING SEGMENTS
TABLE 68. VIRTUS HEALTH: PRODUCT PORTFOLIO
List of Figures
FIGURE 01. FERTILITY SERVICES MARKET: MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP WINNING STRATEGIES, BY YEAR, 2018-2021
FIGURE 04. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018-2021 (%)
FIGURE 05. TOP WINNING STRATEGIES, BY COMPANY, 2018-2021
FIGURE 06. HIGH BARGAINING POWER OF BUYERS
FIGURE 07. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 08. HIGH THREAT OF SUBSTITUTION
FIGURE 09. HIGH THREAT OF NEW ENTRANT
FIGURE 10. MODERATE COMPETITIVE RIVALRY
FIGURE 11. MARKET DYNAMICS
FIGURE 12. ASIA-PACIFIC FERTILITY SERVICES MARKET FOR IVF WITH ICSI, 2020-2030 ($MILLION)
FIGURE 13. ASIA-PACIFIC FERTILITY SERVICES MARKET FOR IUI, 2020-2030 ($MILLION)
FIGURE 14. ASIA-PACIFIC FERTILITY SERVICES MARKET FOR IVF WITHOUT ICSI, 2020-2030 ($MILLION)
FIGURE 15. ASIA-PACIFIC FERTILITY SERVICES MARKET FOR SURROGACY, 2020-2030 ($MILLION)
FIGURE 16. ASIA-PACIFIC FERTILITY SERVICES MARKET FOR OTHERS, 2020-2030 ($MILLION)
FIGURE 17. ASIA-PACIFIC FERTILITY SERVICES MARKET FOR FRESH NON-DONOR, 2020-2030 ($MILLION)
FIGURE 18. ASIA-PACIFIC FERTILITY SERVICES MARKET FOR FROZEN NON-DONOR, 2020-2030 ($MILLION)
FIGURE 19. ASIA-PACIFIC FERTILITY SERVICES MARKET FOR EGG AND EMBRYO BANKING, 2020-2030 ($MILLION)
FIGURE 20. ASIA-PACIFIC FERTILITY SERVICES MARKET FOR FRESH DONOR, 2020-2030 ($MILLION)
FIGURE 21. ASIA-PACIFIC FERTILITY SERVICES MARKET FOR FROZEN DONOR, 2020-2030 ($MILLION)
FIGURE 22. ASIA-PACIFIC FERTILITY SERVICES MARKET FOR FERTILITY CLINICS, 2020-2030 ($MILLION)
FIGURE 23. ASIA-PACIFIC FERTILITY SERVICES MARKET FOR HOSPITALS, 2020-2030 ($MILLION)
FIGURE 24. ASIA-PACIFIC FERTILITY SERVICES MARKET FOR SURGICAL CENTERS, 2020-2030 ($MILLION)
FIGURE 25. ASIA-PACIFIC FERTILITY SERVICES MARKET FOR CLINICAL RESEARCH INSTITUTES, 2020-2030 ($MILLION)
FIGURE 26. APOLLO HOSPITALS: NET SALES, 2018-2020 ($MILLION)
FIGURE 27. APOLLO HOSPITALS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 28. COOPERSURGICAL: NET SALES, 2018-2020 ($MILLION)
FIGURE 29. COOPERSURGICAL: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 30. MEDICOVER: NET SALES, 2018-2020 ($MILLION)
FIGURE 31. MEDICOVER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 32. MEDICOVER: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 33. MVF: NET SALES, 2018-2020 ($MILLION)
FIGURE 34. MVF: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 35. THERMO FISHER SCIENTIFIC: REVENUE, 2018-2020 ($MILLION)
FIGURE 36. THERMO FISHER SCIENTIFIC: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 37. THERMO FISHER SCIENTIFIC: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 38. VIRTUS HEALTH: NET SALES, 2018-2020 ($MILLION)
FIGURE 39. VIRTUS HEALTH: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 40. VIRTUS HEALTH: REVENUE SHARE BY REGION, 2020 (%)
Companies Mentioned
- Apollo Hospitals Enterprise Ltd
- CooperSurgical Inc.
- City Fertility
- ESCO Life Sciences Group
- Fertility Associates Limited
- Genea Limited
- Medicover Group
- Monash IVF Group Limited
- Thermo Fisher Scientific Inc.
- Virtus Health.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 159 |
| Published | August 2021 |
| Forecast Period | 2020 - 2030 |
| Estimated Market Value ( USD | $ 4529.06 million |
| Forecasted Market Value ( USD | $ 20492.95 million |
| Compound Annual Growth Rate | 16.3% |
| Regions Covered | Asia Pacific |
| No. of Companies Mentioned | 10 |
